NEW YORK – Laboratory Corporation of America said Monday that it has entered an agreement to acquire select assets of Lenexa, Kansas-based MAWD Pathology Group for an undisclosed amount.
Under the agreement, Labcorp will acquire portions of the lab's clinical and women's health testing businesses. MAWD will continue to provide comprehensive anatomic professional and technical pathology and related services.
"Labcorp is committed to building upon MAWD Pathology’s long tradition of high-quality laboratory and healthcare services," Bryan Vaughn, senior VP of health systems and the mid-America division at Labcorp, said in a statement. "Through this transaction, physicians, health systems, and their patients will benefit from broader access to Labcorp’s comprehensive testing portfolio while maintaining their deep pathology relationships with MAWD Pathology."
"As we continue to deliver on our core values of quality, service, and respect in every area of our practice, we are also exploring new models to bring greater value and higher levels of care to the communities we serve," Samuel Caughron, president and CEO of MAWD Pathology Group, said in a statement. "We are excited about how our agreement with Labcorp, whose team shares our commitment to improving the health of our communities through best-in-class laboratory services, will advance the highest level of pathology and laboratory care for patients in the region."
The transaction is projected to close in early 2025.